Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis

Blood

Volumn 110, Issue 2, 2007, Pages 606-615

  Cerboni, Cristina ^a   Zingoni, Alessandra ^a,d   Cippitelli, Marco ^a,b   Piccoli, Mario ^a   Frati, Luigi ^a,c   Santoni, Angela ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ATM PROTEIN; ATR PROTEIN; BINDING PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN A; SUPERANTIGEN; UL16 BINDING PROTEIN 1; UL16 BINDING PROTEIN 2; UL16 BINDING PROTEIN 3; UL16 BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL LABELING; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; DNA DAMAGE; DONOR; EXOCYTOSIS; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

EID: 34447104224     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-052720     Document Type: Article

References (68)

1. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002;188:9-21.
2. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol. 2005;3:59-69.
3. Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002;99:1273-1281.
4. Robertson M. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71:173-183.
5. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response. J Immunol. 1999;162:4511-4520.
6. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97:3146-3151.
7. Gray JD, Hirokawa M, Ohtsuka K, Horwitz DA. Generation of an Inhibitory circuit involving CD8 T cells, IL-2, and NK-cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3. J Immunol. 1998;160:2248-2254.
8. Esplugues E, Sancho D, Vega-Ramos J, et al. Enhanced Antitumor Immunity in Mice Deficient in CD69. J Exp Med. 2003;197:1093-1106.
9. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting Natural Killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343-351.
10. Pende D, Castriconi R, Romagnani P, et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood. 2006;107:2030-2036.
11. Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA. NK cell functions restrain T cell responses during viral infections. Eur J Immunol. 2001;31:3048-3055.
12. Schott E, Bonasio R, Ploegh HL. Elimination In Vivo of Developing T Cells by Natural Killer Cells. J Exp Med. 2003;198:1213-1224.
13. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther. 2004;6:8-14.
14. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med. 1997;186:1677-1687.
15. + T cells in a transfer model of colitis. J Immunol. 1998;161:3256-3261.
16. Trivedi PP, Roberts PC, Wolf NA, Swanborg RH. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol. 2005;174:4590-4597.
17. Rabinovich B, Li J, Shannon J, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol. 2003;170:3572-3576.
18. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nature Rev Immunol. 2003;3:781-790.
19. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
20. Bahram S, Inoko H, Shiina T, Radosavljevic M. MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol. 2005;17:505-509.
21. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC Class I-Related Molecules, bind to CMV glycoprotein UL16 and Stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123-133.
22. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 2004;173:1078-1084.
23. Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003;305:129-135.
24. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? Hum Immunol. 2006;67:204-207.
25. Li J, Rabinovich BA, Hurren R, Cosman D, Miller RG. Survival versus neglect: redefining thymocyte subsets based on expression of NKG2D ligand(s) and MHC class I. Eur J Immunol. 2005;35:439-448.
26. Hamerman JA, Ogasawara K, Lanier LL. Cutting Edge: Toll-Like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol. 2004;172:2001-2005.
27. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nature Immunol. 2005;6:938-945.
28. Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/Paracrine IL-15 that is required for type I IFN mediated dendritic cell expression of MHC class I-related chain A and B is impaired in Hepatitis C Virus infection. J Immunol. 2003;171:5423-5429.
29. Schrama D, Terheyden P, Otto K, et al. Expression of the NKG2D ligand UL16 binding protein-1(ULBP-1) on dendritic cells. Eur J Immunol. 2006;36:65-72.
30. Nowbakht P, Ionescu M-CS, Rohner A, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005;105:3615-3622.
31. Molinero L, Fuertes M, Rabinovich G, Fainboim L, Zwirner N. Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol. 2002;71:791-797.
32. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. Cutting Edge: NKG2D is a co-stimulatory receptor for human naive CD8 T cells. J Immunol. 2005;174:4480-4484.
33. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186-1190.
34. + T cell responses against soluble antigens in vivo. J Exp Med. 2005;202:817-828.
35. Zingoni A, Palmieri G, Morrone S, et al. CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur J Immunol. 2000;30:644-651.
36. Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol. 1998;28:3017-3030.
37. Molinero LL, Fuertes MB, Girart MV, et al. NF-KB regulates expression of the MHC Class I-related chain A gene in activated T lymphocytes. J Immunol. 2004;173:5583-5590.
38. Drake C, Kotzin B. Superantigens: biology, immunology, and potential role in disease. J Clin Immunol. 1992;12:149-162.
39. Eagle RA, A.Traherne J, Ashiru O, Wills MR, Trowsdale J. Regulation of NKG2D ligand gene expression. Hum Immunol. 2006;67:159-169.
40. Stephens HAF. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol. 2001;22:378-385.
41. Zhang Y, Lazaro AM, Lavingia B, Stastny P. Typing for all known MICA alleles by group-specific PCR and SSOP. Hum Immunol. 2000;62:620-631.
42. Fodil N, Pellet P, Laloux L, Hauptmann G, Theodorou I, Bahram S. MICA haplotypic diversity. Immunogenetics. 1999;49:557-562.
43. Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA dependent cytotoxicity. Hum Immunol. 2006;67:170-182.
44. Molinero L, Fuertes M, Fainboim L, Rabinovich G, Zwirner N. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol. 2003;73:815-822.
45. Fukao T, Kaneko H, Birrell G, et al. ATM is up-regulated during the mitogenic response in peripheral blood mononuclear cells. Blood. 1999;94:1998-2006.
46. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499-506.
47. + T lymphocytes. Eur J Immunol. 2004;34:2439-2448.
48. Goldstine JV, Nahasb S, Gamob K, et al. Constitutive phosphorylation of ATM in lymphoblastoid cell lines from patients with ICF syndrome without downstream kinase activity. DNA Repair. 2006;5:432-443.
49. Kozlov S, Graham M, Peng C, Chen P, Robinson P, Lavin M. Involvement of novel autophosphorylation sites in ATM activation. EMBO J. 2006;25:3504-3514.
50. Wu Z-H, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science. 2006;311:1141-1146.
51. Golding SE, Rosenberg E, Neill S, et al. Extracellular signal-related kinase positively regulates ataxia telangectasia mutated, homologous recombinant repair, and the DNA damage response. Cancer Res. 2007;67:1046-1053.
52. Tanaka T, Kajstura M, Halicka HD, et al. Constitutive histone H2AX phosphorylation and ATM activation are strongly amplified during mitogenic stimulation of lymphocytes. Cell Prolif. 2007;40:1-13.
53. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999;59:4375-4382.
54. Sabers C, Martin M, Brunn G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815-822.
55. Hickson I, Zhao Y, Richardson J, et al. Identification of a novel and specific inhibitor of the ataxia-telangectasia mutated kinase ATM. Cancer Res. 2004;64:9152-9159.
56. Steinle A, Li P, Morris D, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53:279-287.
57. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1:179-186.
58. Taylor A, Byrd P. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005;58:1009-1015.
59. Huang T, Wuerzberger-Davis S, Wu Z, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell. 2003;115:565-576.
60. Bartkova J, Bakkenist CJ, Meyts ER-D, et al. ATM Activation in normal human tissues and testicular cancer. Cell Cycle. 2005;4:838-845.
61. Yang C, Kastan M. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nature Cell Biol. 2000;2:893-898.
62. Oricchio E, Saladino C, Iacovelli S, Soddu S, Cundari E. ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity. Cell Cycle. 2006;5:88-92.
63. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of non-epithelial origin. Eur J Immunol. 2001;31:1076-1086.
64. Stepp S, Dufourcq-Lagelouse R, Deist FL, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-1959.
65. Matloubian M, Suresh M, Glass A, et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 1999;73:2527-2536.
66. Peng SL, Moslehi J, Robert ME, Craft J. Perforin protects against autoimmunity in lupus-prone mice. J Immunol. 1998;160:652-660.
67. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
68. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.